• MediciNova’s Drug Flunks Phase II Trial biospace
    March 30, 2018
    La Jolla, California-based MediciNova announced that its Phase II clinical trial of ibudilast (MN-166) failed to meet its primary endpoint for methamphetamine dependence.
PharmaSources Customer Service